Key result
Interleukin-1 receptor antagonist exhibits controversial and potential dual effects in the context of obesity and diabetes, with conflicting evidence from different models.
This minireview highlights the controversial and potentially dual effects of IL-1ra in obesity and diabetes, contrasting its known anti-inflammatory benefits with conflicting evidence from knock-out animal models.
Interleukin-1 receptor antagonist (IL-1ra) has been shown to play a crucial role in the prevention of various inflammatory diseases. There is also convincing evidence that IL-1ra is able to counteract inflammatory effects of IL-1 members implicated in insulin resistance and diabetes. However, the use of knock-out animal models provides evidence to the contrary and the role of IL-1ra in obesity-linked anomalies remains controversial. This minireview gets an insight into recent findings on the implication of IL-1ra and its gene polymorphism in diabetes and obesity, discusses the potential dual effects of IL-1ra observed in different models, and comments on future directions.
No takes yet. Share an insight, caveat, or question.
Perrier et al. (2006) conducted a review in Diabetes and obesity. Interleukin-1 receptor antagonist (IL-1ra) was evaluated. Interleukin-1 receptor antagonist exhibits controversial and potential dual effects in the context of obesity and diabetes, with conflicting evidence from different models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: